1Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.J Clin Endocrinol Metab, 2000, 85(10):3575.
2Gault VA, Parker JC, Harriott P, et al.Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol, 2002, 175(2): 525.
3Yip RG, Wolfe MM. GIP biology and fat metabolism. Life SCI, 2000, 66(2): 91.
4Pratley RE, Weyer C. The role of impaired early insulin secretion inpathogenesis of type Ⅱ diabetes mellitus. Diabetologia,2001, 44: 929.
5Lewis JT, Dayanandan B, Habener JF, et al. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology, 2000, 141(10): 3710.
6Meier J J, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secre tion in healthy human subjects at euglycaemia. Diabetologia,2003,46(6): 798.
7Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1)cells by pleiotropic signaling. Mol Endocrinol, 2001, 15(9):1559.
8Trumper A, Trumper K, Horsch D.Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1) cells. J Endocrinol, 2002, 174(2):233.
9Ehses JA, Casilla VR, Doty T, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. En docrinology, 2003, 144 (10): 4433.
10Kindmark H, Pigon J, Efendic S. Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on in sulin extraction. J Clin Endocrinol Metab, 2001, 86(5): 2015.
